All posts by: Michael Zand

Biological Industries USA Announces Mesenchymal Stromal and Stem Cell Research Award, Including Conference …
Business Wire (press release)
CROMWELL, Conn. & BOSTON–(BUSINESS WIRE)–Biological Industries USA (BI-USA), the North American commercial division of Biological Industries, one of the world’s leading suppliers to the life sciences industry, is proud to announce the BI-USA …
New stem cell method aids heart disease researchThe Daily Cardinal
Stem Cell Therapy treats ailments in the body due to aging and other common problemsGood4Utah
Researchers create first stem cells using CRISPR genome activationDrug Target Review
GlobeNewswire (press release) –Nasdaq –UroToday
all 54 news articles »

Tmunity nabs $100M for next-gen T-cell immunotherapies
FierceBiotech
The funding comes from the likes of Ping An Ventures, the Parker Institute for Cancer Immunotherapy, Gilead, the University of Pennsylvania and Lilly Asia Ventures. The “unprecedented” expertise and level of scientific thinking in the founders and …
Xconomy: Tmunity Reels in $100M for “Next Generation” Cancer …Xconomy
Gilead, Parker Institute grab stakes in Penn immunotherapy spinout’s $100 million roundSan Francisco Business Times
Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean …Forbes
Philly.com (blog)
all 12 news articles »

My Two-Decade Journey with Cancer Immunotherapy
Healthline
While cancer patients have relied on surgery, chemotherapy, and radiotherapy seemingly forever, immunotherapy has come of age. It’s now one of the leading wings of cancer drug development, and easily the most written about in the past few years. Among …

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR–T …
Endpoints News
Novartis vet Usman “Oz” Azam and Penn researcher Carl June are two of the ultimate insiders in the CAR–T revolution. They each played prominent roles in advancing Novartis’ breakthrough therapy Kymriah to an historic first-ever approval. They are now …

Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy
Xconomy
Two therapies from the emerging field of engineered T cells won FDA approval to treat blood cancers last year, and the scramble is on to treat more types of cancer. Led by Usman “Oz” Azam (pictured above), the executive who once led Novartis’s cell and …
Tmunity nabs $100M for next-gen T-cell immunotherapiesFierceBiotech
Penn immunotherapy spin-out raises $100MPhiladelphia Business Journal
Cancer startup TMunity raises $100 million to advance next-generation T cell Immunotherapies to transform the …TechStartups.com (blog)
Business Wire (press release) –Forbes –Philly.com (blog)
all 8 news articles »

$100M for Tmunity’s cancer gene therapy from China, US investors
Philly.com (blog)
The investors are led by Ping An Ventures, an arm of China’s largest insurer, which has been plowing profits into biotech; Gilead Sciences, the California-based biopharma company, which in August said it would pay $12 billion for cell therapy developer …
Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean ParkerForbes
Tmunity Reels in $100M for “Next Generation” Cancer ImmunotherapyXconomy
Tmunity Therapeutics Raises $100 Million in Series A Financing to Advance Portfolio of Next-Generation T cell …Digital Journal
San Francisco Business Times –Philadelphia Business Journal
all 10 news articles »

Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean Parker
Forbes
Both attempt to use genetically modified T–cells, which have proven effective in late-stage blood cancers, against more common solid tumors, which are more difficult for the immune system to penetrate. One treatment is what is known as a chimeric …
Tmunity Reels in $100M for “Next Generation” Cancer ImmunotherapyXconomy

all 8 news articles »